These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24606688)

  • 1. Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1.
    Nakano Y; Monde K; Terasawa H; Yuan Y; Yusa K; Harada S; Maeda Y
    Virology; 2014 Mar; 452-453():117-24. PubMed ID: 24606688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.
    Wade J; Sterjovski J; Gray L; Roche M; Chiavaroli L; Ellett A; Jakobsen MR; Cowley D; Pereira Cda F; Saksena N; Wang B; Purcell DF; Karlsson I; Fenyö EM; Churchill M; Gorry PR
    Virology; 2010 Jan; 396(2):246-55. PubMed ID: 19913863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.
    Espy N; Pacheco B; Sodroski J
    Virology; 2017 Aug; 508():90-107. PubMed ID: 28521215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5.
    Monde K; Maeda Y; Tanaka Y; Harada S; Yusa K
    J Biol Chem; 2007 Dec; 282(51):36923-32. PubMed ID: 17971448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
    Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
    Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120.
    Quinlan BD; Joshi VR; Gardner MR; Ebrahimi KH; Farzan M
    J Virol; 2014 Mar; 88(6):3353-8. PubMed ID: 24390333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
    Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
    Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 structural plasticity shapes HIV-1 phenotypic properties.
    Colin P; Zhou Z; Staropoli I; Garcia-Perez J; Gasser R; Armani-Tourret M; Benureau Y; Gonzalez N; Jin J; Connell BJ; Raymond S; Delobel P; Izopet J; Lortat-Jacob H; Alcami J; Arenzana-Seisdedos F; Brelot A; Lagane B
    PLoS Pathog; 2018 Dec; 14(12):e1007432. PubMed ID: 30521629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
    Sterjovski J; Churchill MJ; Ellett A; Gray LR; Roche MJ; Dunfee RL; Purcell DF; Saksena N; Wang B; Sonza S; Wesselingh SL; Karlsson I; Fenyo EM; Gabuzda D; Cunningham AL; Gorry PR
    Retrovirology; 2007 Dec; 4():89. PubMed ID: 18076768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV and SIV gp120 binding does not predict coreceptor function.
    Baik SS; Doms RW; Doranz BJ
    Virology; 1999 Jul; 259(2):267-73. PubMed ID: 10388651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
    Mulampaka SN; Dixit NM
    PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
    Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
    Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development.
    Zhang C; Xu S; Wei J; Guo H
    Int J Infect Dis; 2009 Sep; 13(5):e212-6. PubMed ID: 19217335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.